Amicogen, Inc. announced that it expects to receive KRW 50 billion in funding
June 23, 2021
Share
Amicogen, Inc. (KOSDAQ:A092040) announced a private placement of series 1 unregistered nonguaranteed private convertible bond for gross proceeds of KRW 50,000,000,000 on June 23, 2021. The transaction will include participation from DS Prestige.II Hedge Fund for KRW 44,000,000,000,000, DS K-01 KOSDAQ Venture Hedge Fund for KRW 2,000,000,000, DS N-01 Hedge Fund for KRW 2,000,000,000, DS Best Hedge Fund for KRW 1,000,000,000, DS Lucky Hedge Fund for KRW 1,000,000,000. The bonds will mature on June 28, 2026. The bonds are convertible into 1,203,311 common shares at a price of KRW 41,552 per share. The conversion period is from June 29, 2022 to May 29, 2026. The payment date is June 29, 2021. The transaction has been approved by the board.
Amicogen, Inc. is a Korea-based company engaged in the development, production and distribution of enzymes, bio new materials and healthcare food. The Companyâs products consist of special enzymes, N-acetylglucosamine (NAG), pinitol, D-Chiro-inositol (DCI), collagen peptides (CP) and protein A chromatography resins. The Company distributes its products within domestic market and to overseas markets, including China, Japan, the United Sates, Germany and Thailand.
AMICOGEN, INC. 
